FORT LAUDERDALE - Flora Growth Corp. (NASDAQ: FLGC), a cannabis-focused consumer packaged goods company, has announced a partnership with Sezzle Inc., a leading "buy now, pay later" (BNPL) platform. This collaboration will integrate Sezzle's payment service into Flora's U.S. e-commerce platforms for JustCBD and Vessel, enabling consumers to finance their purchases over time.
JustCBD is known for its diverse range of CBD products, including edibles, tinctures, and skincare items. Vessel offers high-margin cannabis accessories such as vaporizers and storage solutions. Both brands are part of Flora's portfolio, which aims to enhance consumer access to its products.
Sezzle's BNPL service allows customers to split their purchases into multiple payments, offering a flexible alternative to traditional payment methods. This integration aims to leverage the growing consumer demand for more budget-friendly shopping options, as the U.S. BNPL market is expected to exceed $100 billion by 2025.
Clifford Starke, Chairman and CEO of Flora, stated, "We are proud to partner with Sezzle to offer their flexible payment solutions to our U.S. consumers. Whether purchasing CBD products from JustCBD or accessories from Vessel, our customers now have the option to shop on their terms."
The move by Flora Growth reflects a strategic push to improve customer service and purchasing options. As the BNPL market expands, the company is positioning itself to capture a share of the trend towards more accessible payment solutions.
Flora Growth Corp., serving all 50 states and 28 countries, continues to distribute its products globally with a mission to become a leading NASDAQ small-cap international cannabis company. The integration with Sezzle is seen as a step towards enhancing the customer experience and potentially increasing market share in the competitive cannabis and CBD product space.
This business development is based on a press release statement and aims to provide factual information without endorsing any claims.
In other recent news, Flora Growth Corp. has entered into a strategic supply agreement with Blossom Genetics to distribute Colombian medical cannabis strains in Germany, addressing the rising demand following its legalization. The company, which reported Q1 2024 revenues of $18 million, has been operational in Germany since 2017 and is the first to obtain a medical cannabis license in the country. Flora Growth has also formed a joint venture with Althea Group Holdings to enter the U.S. hemp-derived beverage market, each contributing $250,000 of operating capital.
Flora Growth has recently unveiled new branding and launched a redesigned website as part of its global expansion strategy. As part of its compensation arrangements, the company granted significant stock appreciation rights to CEO Clifford Starke and CFO Dany Vaiman. Additionally, the company has regained Nasdaq compliance by appointing Harold Wolkin, a Chartered Financial Analyst, as a new independent director.
The company's subsidiary, JustCBD, introduced two new gummy products aimed at supporting stress management and sleep quality. At the company's 2024 Annual and Special Meeting of Shareholders, several key proposals were approved, including the election of four directors and a significant amendment to the Company's 2022 Incentive Compensation Plan. These are recent developments that are expected to influence the company's direction in the upcoming year.
InvestingPro Insights
As Flora Growth Corp. (NASDAQ: FLGC) embraces innovative payment solutions to enhance customer flexibility, it's important to consider the company's financial health and market performance. According to recent data from InvestingPro, Flora Growth holds a market capitalization of $14.01 million, reflecting its position in the market. Despite the challenging financial metrics with a negative P/E ratio of -0.66 and an adjusted P/E ratio over the last twelve months as of Q2 2024 at -1.45, the company has shown a promising revenue growth of 13.06% during the same period.
InvestingPro Tips suggest that Flora Growth is trading at a low revenue valuation multiple, which could be an indicator of potential undervaluation. Moreover, analysts are optimistic about the company's future, expecting net income and sales growth in the current year. This could be a sign of a turnaround, especially considering the company's recent strategic moves, such as the partnership with Sezzle Inc.
While Flora Growth has experienced significant stock price volatility, it has also demonstrated a strong return over the last week, with a 12.9% price total return. This short-term performance, combined with the anticipated sales growth, may interest investors looking for emerging opportunities in the cannabis sector. For those considering an investment in Flora Growth, there are currently 13 additional InvestingPro Tips available on https://www.investing.com/pro/FLGC, which could provide further insights into the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.